ProfileGDS5678 / 1431033_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 84% 83% 76% 76% 78% 79% 77% 76% 74% 80% 77% 76% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9984676
GSM967853U87-EV human glioblastoma xenograft - Control 26.3135984
GSM967854U87-EV human glioblastoma xenograft - Control 36.1425383
GSM967855U87-EV human glioblastoma xenograft - Control 45.2448976
GSM967856U87-EV human glioblastoma xenograft - Control 55.1450476
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1746778
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3757279
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2189477
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1510676
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9156474
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6705580
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.340377
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0445176
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1727477